Result of AGM

RNS Number : 7264Y
AorTech International PLC
23 August 2018
 

AorTech International plc

("AorTech"or the "Company")

 

Result of AGM

  

AorTech International plc (AIM: AOR), the medical device development company and licensor of the world class bio-stable polymer, Elast-EonTM, announces that all resolutions put to shareholders at its Annual General Meeting held earlier today, were duly passed.

 

 

For further information contact:

 

AorTech International plc                                                            Tel: +44 (0)7730 718296

Bill Brown, Chairman                                                                   

 

Stockdale Scurities Limited                                                         Tel: +44 (0)20 7601 6100

Tom Griffiths/David Coaten                                                         

 

 

About AorTech:

 

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA.  With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

 

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

 

In addition to the licensing of biostable polymers, AorTech is now developing medical devices utilising the key properties of its world class polymers.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGPJMJTMBMTBTP
UK 100

Latest directors dealings